People living with Sicke Cell apprehensive that new treatment Casgevy is here to stay
People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...
New sickle cell treatment approved for NHS use offers patients ‘hope of a cure’
One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
precisionmedicineonline1d
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
STAT1d
Pharmalittle: We’re reading about FDA OK for Vertex non-opioid pain drug, vaccine advisory committee, and more
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
pharmaphorum1d
Vertex bags FDA okay for its non-opioid pain drug
Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...
'Groundbreaking' sickle cell treatment to be offered on NHS
A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell ...
A £1.65m hope for blood disorder patients is now on offer in Manchester
A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...